Literature DB >> 8137263

K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.

N S Pellegata1, F Sessa, B Renault, M Bonato, B E Leone, E Solcia, G N Ranzani.   

Abstract

We studied K-ras and p53 gene mutations in a panel of 57 primary pancreatic cancers including ductal and nonductal tumors. DNAs were obtained from formalin-fixed, paraffin-embedded material. Target sequences were amplified by polymerase chain reaction and analyzed by denaturing gradient gel electrophoresis and sequencing. Both K-ras and p53 genes were frequently mutated in ductal cancers (25 of 35, 71.4%; 18 of 35, 51.4%, respectively). K-ras mutations were confined to the second position of codon 12 where base transitions and transversions were equally observed. p53 changes were mainly missense mutations. Transitions and transversions were found equally with a prevalence of G:C-->A:T changes among transitions. No gene alterations were present in the 6 exocrine nonductal tumors and (with one exception) in the 12 endocrine tumors analyzed. Our results indicate that mutated K-ras and p53 genes can cooperate in the establishment of ductal pancreatic cancers, whereas other genetic events have to be present in nonductal tumors. Moreover, K-ras alterations may represent an early event in ductal tumorigenesis, as suggested both by the high gene mutation frequency and by the presence of mutations in low-grade tumors. On the contrary, p53 gene changes seem to represent an event required for the malignancy progression of ductal tumors from lower to higher grades.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137263

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  102 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Detection of k-ras gene point mutation in fine needle aspiration and pancreatic juice by sequence special primer method and its clinical significance.

Authors:  Xun-Liang Liu; Cun-Cai Dai; Yi Miao; Jing-Hui Du; Zhao-Song Zhang; Shu-Zhen Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 3.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 4.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

5.  The challenge of pancreatic cancer.

Authors:  James L Abbruzzese
Journal:  Int J Gastrointest Cancer       Date:  2003

6.  K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers.

Authors:  K Sugio; K Molberg; J Albores-Saavedra; A K Virmani; Y Kishimoto; A F Gazdar
Journal:  Int J Pancreatol       Date:  1997-06

7.  Effects of a histone deacetylase inhibitor, sodium butyrate, on 53-kDa protein expression and sensitivity to anticancer drugs of pancreatic cancer cells.

Authors:  Masaki Kitazono; Hiroyuki Shinchi; Sumiya Ishigami; Shinichi Ueno; Shoji Natsugoe
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

8.  [Tumors of the endocrine pancreas].

Authors:  M Anlauf; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

9.  Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; R Kucway; W Du; D S Kamarauskiene; V K Vaitkevicius; J D Crissman; F H Sarkar
Journal:  Int J Pancreatol       Date:  1997-04

10.  Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors:  H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.